Development, Validation, and Clinical Application of an HPLC-Based Method for Determining Adenosine Deaminase Activity in Adenosine Deaminase Deficiency-Severe Combined Immunodeficiency
The Journal of Applied Laboratory Medicine · 01.07.2026 · 11 (4) · 758-769
DOI: 10.1093/jalm/jfag037 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift The Journal of Applied Laboratory Medicine, online erschienen am 21.04.2026. Verfasst von Maria Petrik und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia. Hauptthemen laut MEDLINE: Adenosine Deaminase, Severe Combined Immunodeficiency, Agammaglobulinemia, Dried Blood Spot Testing. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
Background
Adenosine deaminase (ADA) deficiency is a rare genetic condition leading to severe combined immunodeficiency. Timely and accurate quantification of ADA activity is crucial for both diagnosis and treatment monitoring. This study describes the development and analytical validation of a high-performance liquid chromatography (HPLC)-based method for measuring ADA activity in dried blood spot (DBS) samples.
Methods
ADA activity was quantified by measuring the enzymatic conversion of adenosine to inosine and hypoxanthine, followed by chromatographic separation and detection. Method validation was conducted according to current bioanalytical guidelines and included assessment of selectivity, linearity, sensitivity, precision, trueness, extraction recovery, and stability. The study involved 3 groups of samples taken from healthy pediatric donors (n = 116), carriers of pathogenic mutations (n = 13), and patients with genetically confirmed ADA deficiency (n = 11).
Results
The assay demonstrated high selectivity and linearity over the tested concentration ranges (coefficient of determination > 0.99 for both analytes). The lower limit of quantification was 0.312 μg/mL (2.29 μmol/L) for hypoxanthine and 0.5 μg/mL (1.86 μmol/L) for inosine. A reference interval for ADA activity in DBS was established at 14.94 to 43.28 nmol/h/mg. The mean ADA activity was 25.06 nmol/h/mg of protein in the control group, 14.08 nmol/h/mg in mutation carriers, and 2.18 nmol/h/mg in patients with ADA deficiency.
Conclusions
The developed method allows precise and reliable determination of ADA activity in DBS. It can be applied for the diagnosis and monitoring of patients with ADA deficiency, as well as in scientific studies related to purine metabolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
- Sechenov University, Moscow, Russia.
ORCID-Profile: Maria Petrik
Förderung
- Russian Science Foundation
Zitieren
APA
Petrik, M., Litvin, E., Osipyants, A., Filkova, A., Rodina, Y., Blinov, D., Grachev, N., & Shcherbina, A. (2026). Development, Validation, and Clinical Application of an HPLC-Based Method for Determining Adenosine Deaminase Activity in Adenosine Deaminase Deficiency-Severe Combined Immunodeficiency. The Journal of Applied Laboratory Medicine, 11(4), 758-769. https://doi.org/10.1093/jalm/jfag037
Vancouver
Petrik M, Litvin E, Osipyants A, Filkova A, Rodina Y, Blinov D, et al. Development, Validation, and Clinical Application of an HPLC-Based Method for Determining Adenosine Deaminase Activity in Adenosine Deaminase Deficiency-Severe Combined Immunodeficiency. The Journal of Applied Laboratory Medicine. 2026;11(4):758-769. doi:10.1093/jalm/jfag037
BibTeX
@article{Petrik2026,
author = {Petrik, Maria and Litvin, Evgeny and Osipyants, Andrey and Filkova, Aleksandra and Rodina, Yulia and Blinov, Dmitrii and Grachev, Nikolay and Shcherbina, Anna},
title = {Development, Validation, and Clinical Application of an HPLC-Based Method for Determining Adenosine Deaminase Activity in Adenosine Deaminase Deficiency-Severe Combined Immunodeficiency},
journal = {The Journal of Applied Laboratory Medicine},
year = {2026},
volume = {11},
number = {4},
pages = {758--769},
doi = {10.1093/jalm/jfag037}
}
EUVIMED